News

The Morningside fund, in the amount of $7.5m, will provide all the required funding needed for the pre-clinical and clinical development plans up to the completion of phase

ValiRx is heading the consortium to take the company’s lead GeneICE product toward human trials and commercialisation. GeneICE compounds are based on proprietary technology, designed for the long-term

Hydrochlorothiazide capsules 12.5mg is the 3,4-dihydro derivative of chlorothiazide. Its chemical name is 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Each capsule contains the following inactive ingredients: colloidal silicon dioxide, corn starch, lactose

The company claims that the 44K array offers increased coverage in known stem cell and cancer associated genes to further enhance the resolution in these functionally important regions.

As per the deal, Taconic gains worldwide rights to distribute a selection of Transposagen’s TKO Knockout Rat Models, developed using advanced mobile DNA technologies. The rat repository currently

Lupin’s Memantine HCL tablets are AB-rated to Namenda tablets, indicated for the treatment of modrate to severe dementia of alzheimer’s type. Vinita Gupta, group president and CEO of

The agreement enables Xbrane Bioscience to distribute and sell the protein expression system for both research and commercial purposes, in addition to utilising the system for their in-house

On January 15, 2010, pursuant to the Hatch-Waxman Act, Watson notified Endo’s partners, Teikoku Seiyaku Co and Teikoku Pharma USA, that its ANDA requesting approval from the FDA

COTI-2 is a molecule that inhibits Akt/PKB (Protein kinase B) phosphorylation which leads to caspase-9 activation in cancer cells resulting in apoptosis or programmed cell death. COTI-2 differs